X4 Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2015
Net Income	-128.91	-101.17	-96.41	-102.64	-62.13	-53.4	Upgrade
Depreciation & Amortization	1.93	2	1.99	1.89	1.23	0.67	Upgrade
Share-Based Compensation	8.78	8.69	5.2	6.18	5.43	2.05	Upgrade
Other Operating Activities	14.6	-6.03	9.57	9.72	-3.35	2.03	Upgrade
Operating Cash Flow	-103.6	-96.51	-77.1	-70.91	-58.82	-48.06	Upgrade
Capital Expenditures	-0.11	-0.06	-0.1	-0.62	-1.36	-0.17	Upgrade
Acquisitions	0	0	0	0	0	26.41	Upgrade
Change in Investments	-20.09	-14.82	0	0	0	1	Upgrade
Investing Cash Flow	-20.2	-14.88	-0.1	-0.62	-1.36	27.23	Upgrade
Share Issuance / Repurchase	69.15	68.71	122.84	74.25	0.28	140.18	Upgrade
Debt Issued / Paid	22.12	20.44	-0.8	0	12.39	0.48	Upgrade
Other Financing Activities	-0.63	-0.63	-4.81	-	-0.28	-	Upgrade
Financing Cash Flow	90.64	88.52	117.23	74.25	12.39	140.66	Upgrade
Exchange Rate Effect	-0.01	0.1	-0.11	-0.32	0.4	-0.25	Upgrade
Net Cash Flow	-33.16	-22.78	39.92	2.41	-47.38	119.59	Upgrade
Free Cash Flow	-103.71	-96.57	-77.21	-71.52	-60.18	-48.23	Upgrade
Free Cash Flow Margin	-	-	-	-	-2006.00%	-	Upgrade
Free Cash Flow Per Share	-0.52	-0.54	-1.22	-2.78	-3.00	-4.18	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).